Anthem Biosciences · NSE: ANTHEM · BSE: 544449
Q3 FY26 results · Oct–Dec 2025
Anthem Biosciences reported revenue from operations of ₹423.15 crore and net profit of ₹92.82 crore for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 423.15 | — | — | 550.03 | −23.1% |
| Other income | 33.53 | — | — | 48.23 | −30.5% |
| Total income | 456.68 | — | — | 598.26 | −23.7% |
| Profit before tax | 130.47 | — | — | 229.60 | −43.2% |
| Net profit for the period | 92.82 | — | — | 173.43 | −46.5% |
| EPS, basic (₹) | 1.65 | — | — | 3.09 | −46.6% |
| Net margin (%) | 21.9 | — | 31.5 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 416.57 | — | — | 552.23 | −24.6% |
| Other income | 39.92 | — | — | 53.80 | −25.8% |
| Total income | 456.50 | — | — | 606.02 | −24.7% |
| Profit before tax | 150.11 | — | — | 253.30 | −40.7% |
| Net profit for the period | 112.12 | — | — | 198.43 | −43.5% |
| EPS, basic (₹) | 2.00 | — | — | 3.54 | −43.5% |
| Net margin (%) | 26.9 | — | 35.9 |
Consolidated
- Filed with BSE
- 05 Feb 2026, 19:26 IST
- Board meeting
- 05 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Feb 2026, 19:26 IST
- Board meeting
- 05 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE